Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of HCC

Cancer
Nadine Abi-Jaoudeh
Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma (HCC)
Liver

Study Description

This is a prospective, multi-center, open-label study to evaluate the effectiveness and safety of Eye90 microspheres® in the treatment of subjects with unresectable Hepatocellular Carcinoma (HCC). Eye90 microspheres is a medical device containing yttrium-90 (Y-90), a radioactive material, and provides local radiation brachytherapy for the treatment of liver tumors.

Eligibility

  • Must be at least 18 years old at the time of informed consent
  • Must have confirmed diagnosis of hepatocellular carcinoma
  • Subjects who are not candidates for ablation, resection, or live transplantation at time of enrollment

-Prior radiation to the liver or lungs

-Prior liver transplant

-History of other cancer within 5 years of the study

A female nurse attentively holds a tablet, ready to assist with patient care and medical information.

Interested in Participating in this Trial?

Thank you for your interest with our team.

One of our specialists will be in contact with you soon.